Barclays’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-70,000
| Closed | -$4.62M | – | 5333 |
|
|
2024
Q3 | $4.62M | Sell |
70,000
-130,000
| -65% | -$9.45M | ﹤0.01% | 2160 |
|
|
2024
Q2 | $18.5M | Buy |
+200,000
| New | +$17.7M | 0.01% | 969 |
|
|
2023
Q2 | – | Sell |
-27,000
| Closed | -$2.23M | – | 4695 |
|
|
2023
Q1 | $2.23M | Buy |
+27,000
| New | +$2.12M | ﹤0.01% | 2112 |
|
|
2020
Q2 | – | Sell |
-78,000
| Closed | -$4.9M | – | 5742 |
|
|
2020
Q1 | $4.9M | Sell |
78,000
-37,500
| -32% | -$2.7M | ﹤0.01% | 1483 |
|
|
2019
Q4 | $8.98M | Buy |
115,500
+44,700
| +63% | +$3.49M | 0.01% | 1484 |
|
|
2019
Q3 | $5.19M | Buy |
70,800
+16,800
| +31% | +$1.18M | ﹤0.01% | 1817 |
|
|
2019
Q2 | $3.33M | Sell |
54,000
-154,500
| -74% | -$9.34M | ﹤0.01% | 2308 |
|
|
2019
Q1 | $13.3M | Buy |
208,500
+61,800
| +42% | +$3.53M | 0.01% | 1056 |
|
|
2018
Q4 | $7.49M | Sell |
146,700
-91,500
| -38% | -$4.63M | 0.01% | 1330 |
|
|
2018
Q3 | $13.8M | Buy |
238,200
+170,700
| +253% | +$8.35M | 0.01% | 1065 |
|
|
2018
Q2 | $3.27M | Buy |
67,500
+40,800
| +153% | +$1.9M | ﹤0.01% | 2098 |
|
|
2018
Q1 | $1.24M | Sell |
26,700
-28,800
| -52% | -$1.25M | ﹤0.01% | 2959 |
|
|
2017
Q4 | $2.08M | Buy |
55,500
+900
| +2% | +$33K | ﹤0.01% | 2387 |
|
|
2017
Q3 | $1.99M | Buy |
54,600
+6,600
| +14% | +$252K | ﹤0.01% | 2372 |
|
|
2017
Q2 | $1.89M | Buy |
48,000
+24,600
| +105% | +$898K | ﹤0.01% | 2302 |
|
|
2017
Q1 | $734K | Sell |
23,400
-43,800
| -65% | -$1.37M | ﹤0.01% | 3031 |
|
|
2016
Q4 | $2.1M | Sell |
67,200
-6,300
| -9% | -$204K | ﹤0.01% | 2088 |
|
|
2016
Q3 | $2.95M | Sell |
73,500
-16,200
| -18% | -$610K | ﹤0.01% | 1676 |
|
|
2016
Q2 | $2.98M | Sell |
89,700
-900
| -1% | -$30.8K | ﹤0.01% | 1696 |
|
|
2016
Q1 | $2.66M | Buy |
90,600
+44,400
| +96% | +$1.23M | ﹤0.01% | 1684 |
|
|
2015
Q4 | $1.2M | Sell |
46,200
-11,400
| -20% | -$296K | ﹤0.01% | 2442 |
|
|
2015
Q3 | $1.36M | Sell |
57,600
-600
| -1% | -$14.5K | ﹤0.01% | 2448 |
|
|
2015
Q2 | $1.38M | Buy |
58,200
+30,600
| +111% | +$691K | ﹤0.01% | 2584 |
|
|
2015
Q1 | $653K | Sell |
27,600
-79,200
| -74% | -$1.78M | ﹤0.01% | 3341 |
|
|
2014
Q4 | $2.26M | Sell |
106,800
-39,600
| -27% | -$796K | ﹤0.01% | 2418 |
|
|
2014
Q3 | $2.49M | Buy |
146,400
+57,000
| +64% | +$900K | ﹤0.01% | 2464 |
|
|
2014
Q2 | $1.27M | Buy |
89,400
+12,600
| +16% | +$171K | ﹤0.01% | 3097 |
|
|
2014
Q1 | $947K | Sell |
76,800
-1,072,800
| -93% | -$12.4M | ﹤0.01% | 3289 |
|
|
2013
Q4 | $12.5M | Sell |
1,149,600
-17,400
| -1% | -$196K | 0.01% | 1090 |
|
|
2013
Q3 | $13.4M | Buy |
1,167,000
+64,200
| +6% | +$751K | 0.02% | 926 |
|
|
2013
Q2 | $12.4M | Buy |
+1,102,800
| New | +$13.1M | 0.02% | 930 |
|
Other funds holding EW
VCM
VPM
Barclays's EW Position: Q1 2026 in Review
Barclays increased its Edwards Lifesciences (EW) stake by 3.2% in Q1 2026, buying an estimated $2.75M and bringing the position to 1,078,481 shares worth $86.4M. The position accounts for 0.02% of the portfolio, ranked #543.
Barclays first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $252M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Barclays held 1,078,481 shares of Edwards Lifesciences worth $86.4M as of Q1 2026.
- Barclays bought 33,366 Edwards Lifesciences shares in Q1 2026, an estimated $2.75M.
- Edwards Lifesciences made up 0.02% of Barclays's portfolio in Q1 2026, its #543 holding.
- Barclays first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- Barclays's Edwards Lifesciences position peaked at $252M in Q4 2021.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.